The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025 ...

For years, conventional wisdom has been that weight loss is a matter of willpower. Those who are overweight or obese just need to try harder to eat less and exercise more. But while diet and ...

We recently compiled a list of the 14 Best Large Cap Dividend Growth Stocks To Buy Now. In this article, we are going to take ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

The price a stock trades ... including Mounjaro (for diabetes) and Zepbound (for weight loss). Together, those two products generated $5.4 billion in sales for Eli Lilly last quarter, or 40% ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE ... From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E ...

Rowe Price highlighted ... of 2024, Eli Lilly and Company (NYSE:LLY) experienced a 45% surge in revenue, reaching $13.53 billion, fueled by strong sales from Mounjaro and Zepbound.